



### LANXESS – Stifel German Corporate Conference Copenhagen

Pandemic year 2020: Successfully managed!

#### Safe harbor statement



The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

### Agenda

1 Executive summary FY 2020 and Q4 2020

2 Financial and business details Q4 2020

3 Back-up



### LANXESS continues to drive its transformation – Proven resilience & more to come!





#### **Strong set-up**

- Four strong segments
- Growing and rising star Consumer Protection
- Leading positions in many niche markets
- Technology & cost leader
- Broad & balanced industry exposure
- Proven track record in reaching our targets



#### How we bring capital to work

- Ongoing portfolio transformation incl. synergies
- Further capital deployment as growth driver
  - Lithium Project as "free option"
  - Attractive debottlenecking projects
  - Battery chemistry as future growth engine
- Digitalization as value catalyst (i.e. Chemondis)
- Strong rebound potential esp. in Engineering Materials and Specialty Additives

Proven resilience demonstrated in pandemic while pressing ahead with transformation

### 2020 highlights: Resilience proven, transformation pushed ahead



#### **Strategic highlights**

#### Portfolio further improved:

- Consumer Protection Division established
- Organic leather chemicals sold to TFL\*
- Realignment of water purification; exit of membranes
- Disposal of CURRENTA gross proceeds of €890 m
- Two bolt-on acquisitions in disinfection\*\*
- Acquisition of Emerald Kalama Chemical signed\*\*

#### ESG acknowledgements:

- Improved MSCI rating to A category
- Recognized by CDP as global climate change leader
- #1 and # 2 in Dow Jones Sustainability Indices

#### **Financial highlights**


- Transformation is paying off:
  - FY EBITDA pre at €862 m decreased only 15% in the midst of global pandemic
  - Margin at 14.1% only 0.9%points lower throughout Corona pandemic
  - Strong FY operating cash flow despite CURRENTA related tax payment
- FY 2020 closed with powerful balance sheet,
   net financial debt reduced to ~€1 bn


<sup>\*</sup> Closing expected by the middle of 2021


### Margin resilience proven amid severe global recession




#### LANXESS faces global pandemic with visible boost in resilience










### Increased dividend despite pandemic





#### **Dividend policy**

### LANXESS aims for an increasing or at least stable dividend



<sup>\*</sup> To be proposed to the Annual General Meeting on May 19, 2021

# Acquisition of Emerald Kalama Chemical: A tailor-made strategic fit!




#### **Key Facts**



- Key Financials 2020 (USD):
  - Sales: ~\$425 m
  - EBITDA pre: ~\$90 m
  - Cash Conversion\*: ~80%
- Enterprise Value: \$1,075 m
   9.0x EBITDA incl. ~\$30 m
   synergies
- EPS accretion: year one expected
- Financed from existing liquidity
- Expected closing: H2 2021

Peers: Valtris, Eastman, Celanese



#### **Key Rationale**

- Specialty business with strong fit to current portfolio
- Vertically integrated into high value derivatives\*\*
- Strategic expansion into growth markets Food and Animal Nutrition
- Attractive secular growth markets above GDP
- Highly synergistic, both cost and top line synergies
- Straight forward integration into LANXESS

<sup>\*</sup> cash conversion = EBITDApre - CAPEX / EBITDApre (mid-term)

<sup>\*\*</sup> based on Benzoic acid & Benzaldehyde

# **Emerald Kalama Chemical offers a 100% complementary fit to LANXESS**



### LANXESS Consumer Protection



#### **Consumer Specialties (~75%)**

#### **Animal Health**

- Preservatives for feed silage
- Animal feed additives substituting anti-biotics

Growth > GDP



#### Flavours & Fragrances

 ~30 aroma ingredients for food, home & personal care products



Growth > GDP

#### Food & Beverage

 High quality preservatives for food and beverages

Growth ~ GDP



#### **Home & Personal Care**

 Nature identical high purity preservatives for cleaning applications & cosmetics

Growth ~ GDP



#### **Industrial Specialties (~25%)**

#### **CASE\* & Polymers**

- Phthalate-free plasticizers for:
  - Construction materials: e.g. flooring, sealants
  - Adhesives: substitution for mechanical fastening
  - Coatings and paper-based packaging



Growth > GDP

# Acquisition of Emerald Kalama Chemical strengthens LANXESS as a leading Consumer Protection player



#### Balanced specialties portfolio with long-term secular growth drivers

#### **Consumer Protection: Focus areas**



**Animal Health** 



F&B / F&F\*



Water Purification



**Agro** 

- Backward integrated leader in microbial solutions
- Strengthening competitiveness
- Leading position in future growth business
- Strong position in custom manufacturing


#### **Future growth enablers**

- Animal Health: Antibiotic substitution and rising pests globally
- Regulatory trend: Global boost in regulation for active ingredients
- Need for preservation: Increasing demand for plastic-free packaged & processed food
- Natural trend: Rising demand and awareness for natural & hygienic solutions
- Water scarcity: High-tech products for topnotch technology players
- Agro recovery: additional upside to contract based growth

### The combined product portfolio brings consumer protection to everyone's daily life



#### Emerald Kalama's products complement LANXESS' Consumer Protection portfolio perfectly



<sup>\*\*</sup> Additives: e.g. Active Ingredients & Intermediates (Pharma); Processing Agents (Food)


### Acquisition of Emerald Kalama Chemical provides attractive synergy potential for LANXESS



**Overview: Synergies structure** 

**Phasing: Synergies, OTCs and CAPEX** 

Illustrative



### **Emerald Kalama Chemical ideally complements LANXESS growth in Consumer Protection**



100% strategic fit

Strengthened competitiveness in Consumer Protection end markets

Secular growth

Long-term trend driven growth above GDP

High synergies/
Low complexity


Extended and complementary portfolio offers significant high synergies

Low integration risk – low complexity (only three sites)

**Attractive** financials

Solid 9.0x EBITDA multiple (post synergies)

Cash Conversion ~80%\* and EPS accretion in year one



### **Strongest Q4 since 2012**



#### **Q4 Highlights**

- EBITDA pre at €200 m above previous year and best since 2012 despite unplanned outage and FX headwinds
- Positive business momentum strengthened in Q4
- Strong operating Cash Flow despite CURRENTA related tax payments
- FY 2020 closed with powerful balance sheet, net financial debt reduced to ~€1 bn



### LANXESS' commitment to sustainability now also reflected in Board remuneration



CDP – Climate: A ranked






Admittance in Bloomberg Gender Equality Index



### Top in Dow Jones Sustainability Index

Dow Jones
Sustainability Indices
In Collaboration with RobecoSAM



#### Say-on-pay in this year's AGM on May 19


- New system¹ for Board remuneration reflecting LANXESS' commitment to sustainability by considering ESG components in:
  - Short term incentive plan (STI):
     safety performance related
  - Long term incentive plan (LTI): focused on absolute CO<sub>2</sub> reduction<sup>2</sup>


<sup>&</sup>lt;sup>1</sup>New system approved by supervisory board, in effect since January 1, 2021, but still subject to AGM approval

<sup>&</sup>lt;sup>2</sup> The CO<sub>2</sub> target was set as the first target for the LTI

### Optimistic for FY 2021: Recovery expected







#### **Current view on economy**

- Sequential recovery in most end markets:
  - Strong rebound in Automotive, Agro, Construction, Chemicals to improve slightly
  - Aviation still weak, Oil & Gas gradually improving
  - Soaring raw mat. prices trigger typical time lag for pass-through
- Uncertainty persists

#### **LANXESS outlook FY 2021**

- FY EBITDA pre expected €900 €1,000 m
- Q1 with nice sequential momentum: €200-250 m EBITDA pre expected, however burden of
  - YoY full pandemic impact
  - Weather-related US plant shutdowns (~€10 m)
  - Weak US Dollar

### Optimistic for FY 2021: Strongest rebound in Engineering Materials





#### **Advanced Intermediates – On or slightly above prior year level**

- Recovery in BU All's broadly diversified end markets, energy prices are a burden
- Good development in construction (BU IPG)





#### **Specialty Additives – Significantly above prior year**

- Improvement in Lubricant Additives
- Auto recovery, also helped by reorganization of rubber additives





#### **Consumer Protection – Slightly above prior year level**

- Strong demand to continue
- Already high utilization for disinfection and water purification limits volume growth





#### **Engineering Materials – Significantly above prior year**

- Strong auto recovery
- No burden from maintenance turnaround and unplanned shutdown (H2 2020)



### Agenda

1 Executive summary FY 2020 and Q4 2020

2 Financial and business details Q4 2020

3 Back-up




# LANXESS Group: Increased earnings despite high comparable base



# Resilience proven, margin improved!

| [€ m]*     | Q4/2019 | Q4/2020 | Δ    | FY 2019 | FY 2020 | Δ    |
|------------|---------|---------|------|---------|---------|------|
| Sales      | 1.636   | 1.503   | -8%  | 6.802   | 6.104   | -10% |
| EBITDA pre | 197     | 200     | 2%   | 1.019   | 862     | -15% |
| Margin     | 12,0%   | 13,3%   |      | 15,0%   | 14,1%   |      |
| CAPEX      | 213     | 192     | -10% | 508     | 456     | -10% |



- Sales decline driven by pass-through of lower raw material prices, volume impact (unplanned shutdown) and adverse FX effect
- EBITDA pre accelerates compared to strong previous year base driven by higher utilization and cost containment measures

<sup>\*</sup> All figures excluding BU LEA, which is reported as discontinued operation



### Advanced Intermediates: Recovery materializes



# Rising volumes, strong profitability

| [€ m] <sup>*</sup> | Q4/2019 | Q4/2020 | Δ    | FY 2019 | FY 2020 | Δ    |
|--------------------|---------|---------|------|---------|---------|------|
| Sales              | 533     | 502     | -6%  | 2.251   | 1.999   | -11% |
| EBITDA pre         | 73      | 83      | 14%  | 383     | 336     | -12% |
| Margin             | 13,7%   | 16,5%   |      | 17,0%   | 16,8%   |      |
| CAPEX              | 62      | 53      | -15% | 161     | 145     | -10% |



- Improved sales volume offset by raw material price effect and FX
- Momentum in end industries further improves, especially in construction
- EBITDA pre and margin above previous year due to higher volumes and better utilization

<sup>\*</sup> New reporting structure as of Q1 2020 excluding BU SGO and including BU Inorganic Pigments



# **Specialty Additives: Pronounced margin resilience**



# Volumes compare to strong previous year

| [€ m]      | Q4/2019 | Q4/2020 | Δ    | FY 2019 | FY 2020 | Δ    |
|------------|---------|---------|------|---------|---------|------|
| Sales      | 471     | 416     | -12% | 1.965   | 1.728   | -12% |
| EBITDA pre | 84      | 71      | -15% | 353     | 284     | -20% |
| Margin     | 17,8%   | 17,1%   |      | 18,0%   | 16,4%   |      |
| CAPEX      | 47      | 38      | -19% | 120     | 94      | -22% |



- Sales decline due to lower volumes and burdening FX
- Ongoing weakness in aviation and oil & gas impacted volumes, auto recovery starting to come through
- Price reductions following lower raw material prices
- EBITDA pre decline reflects weak demand and negative FX effect, only slight margin decrease thanks to cost containment measures



# **Consumer Protection: Earnings continue to grow**



# Profitability improved again

| [€ m]*     | Q4/2019 | Q4/2020 | Δ   | FY 2019 | FY 2020 | Δ   |
|------------|---------|---------|-----|---------|---------|-----|
| Sales      | 262     | 252     | -4% | 1.050   | 1.110   | 6%  |
| EBITDA pre | 35      | 39      | 11% | 198     | 233     | 18% |
| Margin     | 13,4%   | 15,5%   |     | 18,9%   | 21,0%   |     |
| CAPEX      | 26      | 32      | 23% | 61      | 69      | 13% |



- Moderate sales decline due to lower volumes and FX impact, strong contribution from acquisition in Brazil
- Volumes decrease due to IFRS 15 effects, FX burdens additionally
- Slight price increase across segment
- Strong EBITDA pre increase driven by improved prices and contribution from acquisition in Brazil

<sup>\*</sup> New reporting structure as of Q1 2020, data excluding BU LEA, which is reported as discontinued operation




# **Engineering Materials: Auto recovery mitigates effects from unplanned shutdown**



# Solid margin despite outage

| [€ m]      | Q4/2019 | Q4/2020 | Δ    | FY 2019 | FY 2020 | Δ    |
|------------|---------|---------|------|---------|---------|------|
| Sales      | 350     | 314     | -10% | 1.450   | 1.190   | -18% |
| EBITDA pre | 49      | 41      | -16% | 238     | 151     | -37% |
| Margin     | 14,0%   | 13,1%   |      | 16,4%   | 12,7%   |      |
| CAPEX      | 51      | 47      | -8%  | 104     | 86      | -17% |



- Sales decrease mainly due to pass-through of lower raw material prices and negative FX impact
- Strong recovery in auto demand, however volume decline resulting from unplanned shutdown in BU HPM. Sequential improvement accelerates
- EBITDA pre and margin stabilize visibly even despite force majeure in BU HPM

### P&L: Best Q4 in new company set-up




| [€ m]*             | Q4/2019 |        | Q4/2020 |         | yoy in % |
|--------------------|---------|--------|---------|---------|----------|
| Sales              | 1.636   | (100%) | 1.503   | (100%)  | -8%      |
| Cost of sales      | -1.253  | (-77%) | -1.126  | (-75%)  | -10%     |
| Selling            | -203    | (-12%) | -193    | (-13%)  | -5%      |
| G&A                | -81     | (-5%)  | -72     | (-5%)   | -11%     |
| R&D                | -30     | (-2%)  | -28     | (-2%)   | -7%      |
| EBIT               | 0       | (0%)   | 35      | (2%)    | >100%    |
| EPS                | -0,25   |        | 0,20    |         | >100%    |
| EPS pre            | 0,64    |        | 0,82    |         | 28%      |
| EBITDA             | 160     | (10%)  | 170     | (11%)   | 6%       |
| thereof except.    | -37     | (-2%)  | -30     | (-2%)   | -19%     |
| EBITDA pre except. | 197     | (12%)  | 200     | (13,3%) | 2%       |


- Improvement in SG&A and R&D reflect cost containment measures
- Higher earnings, margins and EPS due to recovering demand despite unplanned shutdown

<sup>\*</sup> From continuing operations

# Q4 2020: Consumer Protection and recovery in Advanced Intermediates drive strong result








<sup>\*</sup> Total group sales including reconciliation

# Q4 2020: Impact from pandemic still visible in all regions, sales decline reflects lower raw material prices





<sup>\*</sup> Currency and portfolio adjusted

# Operating cash flow improved, but masked by extraordinary tax payment related to Currenta disposal



| [€ m]                               | Q4/2019 | Q4/2020 | Δ   |
|-------------------------------------|---------|---------|-----|
| Operating cash flow*                | 267     | 262     | -5  |
| thereof income taxes paid           | -39     | -80     | -41 |
| thereof changes in working capital  | 212     | 204     | -8  |
| Investing cash flow*                | -270    | -289    | -19 |
| thereof capex                       | -213    | -192    | 21  |
| thereof net invest in money markets | -82     | -100    | -18 |

- Strong operating cash flow despite mid to high double digit million tax payment relating to CURRENTA divestment
- Ongoing tight working capital management
- Capex reduced in response to pandemic

<sup>\*</sup> Applies to continuing operations

### **Ongoing strong balance sheet**



| [€ m]   | 31.12.2019 | 30.09.2020 | 31.12.2020 |
|---|------------|------------|------------|
| Total assets  | 8.695      | 8.850      | 8.880      |
| Equity  | 2.647      | 3.167      | 2.999      |
| Equity ratio  | 30%        | 36%        | 34%        |
| Net financial debt <sup>1</sup>                     | 1.742      | 1.150      | 1.012      |
| Cash, cash equiv., short-<br>term money market inv. | 1.076      | 1.657      | 1.794      |
| Pension provisions                                  | 1.178      | 1.083      | 1.205      |
| Net working capital                                 | 1.308      | 1.358      | 1.134      |
| DSI (in days) <sup>2</sup>                          | 66         | 70         | 64         |
| DSO (in days) <sup>3</sup>                          | 42         | 47         | 45         |

- Strong liquidity further improved supported by CURRENTA disposal; secures financial and operating flexibility
- Increase in pension provisions due to lower interest rates
- Usual year-end decrease in working capital

<sup>&</sup>lt;sup>1</sup> Including cash, cash equivalents, short-term money market investments

<sup>&</sup>lt;sup>2</sup> Days sales of inventory calculated from quarterly sales

<sup>&</sup>lt;sup>3</sup> Days of sales outstanding calculated from quarterly sales

### Agenda

1 Executive summary FY 2020 and Q4 2020

2 Financial and business details Q4 2020

3 Back-up



### Housekeeping items 2021



**Capex 2021** 

Operational D&A 2021

**Reconciliation 2021** 

Underlying tax rate

Exceptionals 2021

FX sensitivity

Remnant costs

~€450-500 m

~€450 m

~€150-160 m including remnant costs and re-occurring expenses

~28%

€70-100 m based on current initiatives

One cent change of USD/EUR resulting in **~€7 m** EBITDA pre impact before hedging

2021: Additional remnant costs of ~€5 m (50% of organic leather business due to expected closing mid 2021)

2022: Additional remnant costs of ~€5 m (impact of organic leather business fully effective)

# LANXESS CAPEX spendings foster an efficient asset base and attractive growth



Priority to profitable growth (ROCE ~ 20%) instead of Cash Conversion\* target (>60%) fulfillment


CAPEX outlook & spendings 2021

#### Outlook 2021

Digital. & CO₂ projects: up to €50 m

Organic growth: ~€100 – 150 m

Maintenance: ~€300 m



### **Key Figures\*: Holding up well in crisis mode**



Q3 **Q4** 





€262m **Operating Cash** Flow



€1,794 m Cash & cash equivalents, short term money market investments



+2%

€200 m EBITDA pre



13.3% EBITDA pre Margin



€1,012 m Net financial debt\*\*



0.82

+28%



<sup>\*</sup> Continuing operations (excluding BU LEA, which is reported as discontinued operation)

<sup>\*\*</sup> deducting short-term money market investments

### FY 2020: EBITDA pre only declines 15% in Corona crisis LAN)



| [€ m]*             | FY 2019 |        | FY 2020 |         | yoy in % |
|--------------------|---------|--------|---------|---------|----------|
| Sales              | 6.802   | (100%) | 6.104   | (100%)  | -10%     |
| Cost of sales      | -5.043  | (-74%) | -4.548  | (-75%)  | -10%     |
| Selling            | -812    | (-12%) | -773    | (-13%)  | -5%      |
| G&A                | -274    | (-4%)  | -267    | (-4%)   | -3%      |
| R&D                | -114    | (-2%)  | -108    | (-2%)   | -5%      |
| EBIT               | 407     | (6%)   | 253     | (4%)    | -38%     |
| EPS                | 2,72    |        | 10,49   |         | > 100    |
| EPS pre            | 4,73    |        | 3,50    |         | -26%     |
| EBITDA             | 910     | (13%)  | 757     | (12%)   | -17%     |
| thereof except.    | -109    | (-2%)  | -105    | (-2%)   | -4%      |
| EBITDA pre except. | 1.019   | (15%)  | 862     | (14,1%) | -15%     |

- Corona-based drop in demand is key driver for decline in results
- Lower selling expenses and R&D result from cost containment measures; reduced G&A costs offset by remnant cost from several divestments
- Positive effects from CURRENTA divestment reflected in financial result and EPS
- EBITDA pre decline of only 15% proves LANXESS resilience

<sup>\*</sup> From continuing operations

### Cash flow FY 2020: Solid operating cash flow despite Corona crisis




| [€ m]   | FY 2019 | FY 2020 | Δ    |
|---|---------|---------|------|
| Operating cash flow*                          | 634     | 594     | -40  |
| thereof income taxes paid                     | -193    | -215    | -22  |
| Changes in working capital                    | 68      | 106     | 38   |
| Investing cash flow*                          | -697    | -350    | 347  |
| thereof capex                                 | -508    | -456    | 52   |
| thereof proceeds from divestments & dividends | 41      | 971     | 930  |
| thereof net invest in money markets           | -241    | -749    | -508 |
| thereof pension funding                       | 0       | -100    | -100 |

- Strong operating cash flow improvement after adjustment of CURRENTA related tax payments
- Ongoing tight working capital management
- Lower capex reflect measures triggered by Corona pandemic
- Investing cash flow includes proceeds from divestments of CURRENTA and chrome chemicals business which are mainly invested in money market funds
- Investing cash flow includes
   €100 m voluntary pension funding

<sup>\*</sup> Applies to continuing operations

# FY 2020: More resilient business set-up – only 15% EBITDA pre decline despite pandemic






<sup>\*</sup> Total group sales including reconciliation

# FY 2020: Impact from pandemic still visible in all regions, sales decline reflect lower raw material prices





<sup>\*</sup> Currency and portfolio adjusted

# Exceptional items (on EBIT) below previous year level, resulting from further restructuring and project costs



| [€ m]  | Q4/    | 2019           | Q4/    | 2020           | FY     | 2019           | FY     | 2020           |   |
|--|--------|----------------|--------|----------------|--------|----------------|--------|----------------|---|
|  | Excep. | Thereof<br>D&A | Ехсер. | Thereof<br>D&A | Ехсер. | Thereof<br>D&A | Ехсер. | Thereof<br>D&A | Comments  |
| Strategic Realignment & Restructuring            | 57     | 37             | 18     | 17             | 76     | 39             | 68     | 35             | incl. adjustment of production network, impairment Membranes €17m         |
| M&A, Digitalization (incl. Chemondis) and Others | 11     | 1              | 19     | 1              | 49     | 1              | 47     | 2              | incl. CUR, LEA, OMS and membrane divestments, acquistions in disinfection |
| Strategic IT projects                            | 7      | 0              | 12     | 1              | 25     | 1              | 28     | 1              | incl. SAP Hana Project  |
| Total  | 75     | 38             | 49     | 19             | 150    | 41             | 143    | 38             |   |


### Maturity profile actively managed and well balanced



#### **Long-term financing secured**

- Diversified financing sources
  - Bonds & private placements
  - Undrawn sustainable revolving credit facility
- Average interest rate of financial liabilities ~2%
- Next bond maturity in October
- All group financing executed without financial covenants


#### Liquidity and maturity profile as per December 2020



<sup>\*</sup> Hybrid bond with contractual maturity date in 2076 has a first optional call date in 2023.

# On track to climate neutrality in 2040: Nitrous oxide reduction in Antwerp





#### Milestone in our climate strategy

- Nitrous oxide is generated during caprolactam production
- Investment of approx. EUR 10 million


Plant significantly reduces emissions: 150 kt CO<sub>2</sub>e / year less



2 Second plant planned for 2023 Impact: 300 kt CO<sub>2</sub>e / year less

# Upcoming virtual events 2021 - Proactive capital market communication





#### **Contact details Investor Relations**





**Oliver Stratmann Head of Treasury & Investor Relations** 

Tel.: +49 221 8885 9611 Fax.: +49 221 8885 5400 Mobile: +49 175 304 9611





**Mirjam Reetz** Private Investors

Tel.: +49 221 8885 1272 Mobile: +49 151 7461 3158 Email: Mirjam.Reetz@lanxess.com



Lisa Häckel Investor Relations Assistant

Tel.: +49 221 8885 9834 Mobile: +49 151 7461 4637 Email: Lisa.Haeckel@lanxess.com



**André Simon Head of Investor Relations** 

Tel.: +49 221 8885 3494 Mobile: +49 175 302 3494 Email: Andre.Simon@lanxess.com



**Eva Frerker** Institutional Investors / Analysts

Tel.: +49 221 8885 5249 Mobile: +49 151 7461 2969 Email: Eva.Frerker@lanxess.com



Jens Ussler Institutional Investors / Analysts

Tel.: +49 221 8885 7344 Mobile: +49 151 7461 2913 Email: Jens.Ussler@lanxess.com





#### **Abbreviations**





#### **Advanced Intermediates**

All Advanced Industrial Intermediates

IPG Inorganic Pigments



#### **Consumer Protection**

LPT Liquid Purification Technologies

MPP Material Protection Products

SGO Saltigo



#### **Specialty Additives**

**LAB** Lubricant Additives Business

**PLA** Polymer Additives

**RCH** Rhein Chemie



#### **Engineering Materials**

**HPM** High Performance Materials

**URE** Urethane Systems

# LANXESS Energizing Chemistry